The Butantan creates new technologies and industrial processes for vaccines and other immunobiologicals, supplying 150 million doses of antigen vaccines per year, which constitute 82% of all vaccines in the country, at affordable prices which are provided free to all children and older adults. New developments include a pertussis vaccine that can be produced at the same price as the traditional vaccine by a process also yields an adjuvant which increase the efficacy of seasonal and avian influenza vaccines four-fold, reducing cost and increasing plant capacity; a technology which results in the highest industrial yield of human rabies vaccine to date a combined vaccine in the maternity for BCG-hepatitis B and pertussis and developed lung surfactant that will decrease prenatal mortality not solve with vaccines. In collaboration with NIH, Path and PDVI the Butantan is starting the production and assay of rotavirus and dengue vaccines.
Raw, I., & Higashi, H. G. (2008). Auto-suficiência e inovação na produção de vacinas e saúde pública. Estudos Avancados, 22(64), 155–170. https://doi.org/10.1590/S0103-40142008000300010
Mendeley helps you to discover research relevant for your work.